Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Creative Commons License

Efe C., Hagstrom H., Ytting H., Bhanji R. A., Muller N. F., Wang Q., ...Daha Fazla

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, cilt.15, sa.12, ss.1950-1957, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.cgh.2017.06.001
  • Dergi Adı: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1950-1957
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND & AIMS: Predniso(lo) ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.